A number of other equities analysts also recently issued reports on the stock. Deutsche Bank AG set a €17.00 ($19.77) price objective on shares of Evotec AG and gave the stock a neutral rating in a report on Monday, November 6th. Berenberg Bank set a €16.00 ($18.60) price objective on shares of Evotec AG and gave the stock a neutral rating in a report on Wednesday. Finally, Oddo Securities set a €14.00 ($16.28) price objective on shares of Evotec AG and gave the stock a neutral rating in a report on Friday, August 11th.
Shares of Evotec AG (ETR:EVT) opened at €15.60 ($18.14) on Thursday. Evotec AG has a 1-year low of €4.85 ($5.64) and a 1-year high of €22.50 ($26.16).
WARNING: “Oddo Bhf Analysts Give Evotec AG (EVT) a €20.00 Price Target” was first reported by Markets Daily and is the sole property of of Markets Daily. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.themarketsdaily.com/2017/11/12/oddo-bhf-analysts-give-evotec-ag-evt-a-20-00-price-target.html.
Evotec AG Company Profile
Evotec AG provides drug discovery solutions to the pharmaceutical and biotechnology companies, academic institutions, and foundations and not-for-profit organizations worldwide. The company operates through two segments, EVT Execute and EVT Innovate. It offers drug discovery services, such as integrated services, target identification and validation, hit identification, compound management, chemistry, drug metabolism and pharmacokinetics, research informatics and in silico drug discovery, proteomics and metabolomics, cell and protein production, and in vivo and in vitro pharmacology services.
Receive News & Ratings for Evotec AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec AG and related companies with MarketBeat.com's FREE daily email newsletter.